Jason Westin MD

Hematologic Oncology

Physician

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Dr. Westin is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Westin's full profile Already have an account?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of North Carolina HospitalsResidency, Internal Medicine, 2002 - 2005
University of Florida College of MedicineClass of 2002

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
GA State Medical License 2023 - 2028
AZ State Medical License 2023 - 2027
LA State Medical License 2023 - 2027
MS State Medical License 2023 - 2027
OK State Medical License 2020 - 2027
TN State Medical License 2023 - 2027
WA State Medical License 2023 - 2027
AL State Medical License 2023 - 2026
TX State Medical License 2006 - 2026
NC State Medical License 2002 - 2007
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2014-2015

Clinical Trials

Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Start of enrollment: 2016 Mar 29
COMPLETED
PHASE2
Phase II Study of TAK228 in Relapsed Lymphoma Start of enrollment: 2017 Mar 01
TERMINATED
PHASE1, PHASE2
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas Start of enrollment: 2017 Feb 06
COMPLETED
PHASE1

Publications & Presentations

PubMed

A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.
L Elizabeth Budde, Adam J Olszewski, Bei Hu, Nikesh N Shah, Connie Lee Batlevi
Ejhaem. 2026-08-01
Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the p...
Dai Maruyama, Hideki Goto, Takahiro Kumode, Keiko Aizawa, Noriko Fukuhara
International Journal of Clinical Oncology. 2026-08-01
Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma.
Dai Chihara, Kumudha Balakrishnan, Gita Masand, Robert Andrew Harkins, Neha Akkad
Blood Advances. 2026-07-24

Journal Articles

Assessment of Radiation Doses Delivered to Organs at Risk Among Patients with Early-Stage Favorable Hodgkin Lymphoma Treated with Contemporary Radiation Therapy
Chelsea C Pinnix, Jillian R Gunther, Sarah A Milgrom, Jason Westin, Simrit Parmar, Loretta Nastoupil, Sattva Neelapu, Bouthaina S Dabaja, JAMA Network Open

Abstracts/Posters

A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma
Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
Jason R. Westin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-c...
2019 ASCO Annual Meeting - 6/1/2019
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

U.S. Oncology Drug Supply Remains Stable Amid Ongoing Conflict in the Middle East U.S. Oncology Drug Supply Remains Stable Amid Ongoing Conflict in the Middle EastApril 13th, 2026
Immunotherapy Combination Active in Patients with Large B-cell Lymphoma Who Are Not Eligible for Autologous Stem Cell TransplantNovember 10th, 2025
Tox Check: Chimeric Antigen Receptor T-Cell TherapyJanuary 7th, 2025